Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Eledon Pharmaceuticals logo
$3.31 +0.03 (+0.91%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.27 -0.04 (-1.21%)
As of 05/2/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Key Stats

Today's Range
$3.29
$3.47
50-Day Range
$2.71
$4.26
52-Week Range
$2.00
$5.54
Volume
96,113 shs
Average Volume
284,948 shs
Market Capitalization
$198.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
Consensus Rating
Buy

Company Overview

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

ELDN MarketRank™: 

Eledon Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 771st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eledon Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Eledon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eledon Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eledon Pharmaceuticals is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eledon Pharmaceuticals is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eledon Pharmaceuticals has a P/B Ratio of 11.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eledon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.32% of the float of Eledon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently increased by 19.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eledon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eledon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.32% of the float of Eledon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently increased by 19.86%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eledon Pharmaceuticals has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for ELDN on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.70% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eledon Pharmaceuticals' insider trading history.
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELDN Stock News Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Guggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)
See More Headlines

ELDN Stock Analysis - Frequently Asked Questions

Eledon Pharmaceuticals' stock was trading at $4.12 at the start of the year. Since then, ELDN stock has decreased by 19.7% and is now trading at $3.31.
View the best growth stocks for 2025 here
.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) issued its quarterly earnings data on Thursday, March, 20th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.32.

Eledon Pharmaceuticals' top institutional shareholders include Alps Advisors Inc. (0.07%).
View institutional ownership trends
.

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/20/2025
Today
5/03/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$16.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+277.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-116,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.30 per share
Price / Book
11.03

Miscellaneous

Free Float
52,750,000
Market Cap
$198.21 million
Optionable
Optionable
Beta
0.66
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ELDN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners